A large retrospective study of kidney transplant recipients found no longevity benefit from chronic rapamycin use after follow-up exceeding a decade, including after adjustment for patient differences. The analysis suggests that observational signals favoring rapamycin-based strategies do not translate into measurable survival advantage in this long-term transplant population. For clinicians considering mTOR inhibition as an immunosuppression or long-term risk-modifying approach, the practical takeaway is that dose duration and patient selection may be critical—yet the overall longevity effect was not observed. The study also reinforces how difficult it can be to infer causal survival benefits from registry and retrospective designs in heterogeneous transplant cohorts.